Reduced Anxiety Level by Therapeutic Interventions and Cell-Mediated Immunity in Panic Disorder Patients
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective: This study examined the relationship between reduced anxiety level by therapeutic interventions and cell-mediated immunity (CMI) in patients with panic disorder. Methods: The subjects consisted of 42 patients with panic disorder and 42 normal gender- and age-matched controls. Among the patients, 21 were randomly assigned to a combined treatment of cognitive-behavioral therapy and the benzodiazepine antianxiety agent ethyl loflazepate (2 mg daily), and 21 were assigned to the antianxiety agent only. The treatment lasted for 6 weeks. Cell-mediated immune function was measured by the lymphocyte proliferative response to phytohemagglutinin (PHA) and interleukin-2 (IL-2) production. The anxiety level was assessed by the Hamilton Rating Scale for Anxiety and the anxiety subscale of the Symptom Checklist-90 Revised. Results: Prior to treatment, the panic disorder patients had significantly lower IL-2 production and blastogenic response to PHA than the normal controls. However, no significant differences in CMI were found between the pretreatment and posttreatment period in either the patient group receiving medication only or the combined treatment group, though after treatment, patients were significantly less anxious than before treatment in both intervention groups. The delta change (posttreatment value minus pretreatment value) in the self-reported anxiety level was significantly associated with the delta change in the blastogenic response in the combined treatment group. Conclusion: These findings suggest that panic disorder may be associated with decreased CMI, and the reduced level of self-reported anxiety in the patients who underwent combined therapeutic intervention is likely to increase the blastogenic response. Further studies are needed to evaluate the long-term effects of treatment on immune function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, IL-4 and IL-2 have also been found to be increased in PD (Hoge et al, 2009;Koh and Lee, 2004;Rapaport and Stein, 1994) or not different from controls in individuals with PD (Tukel et al, 2012).”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee, 2004
In the citing paper
“| Interleukin-2 | Decreased in GAD | Koh and Lee (2004),Rapaport and Stein (1994), and Vieira et al (2010) |”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee (2004)
In the citing paper
“| Interleukin-2 | Decreased in GAD | Koh and Lee (2004),Rapaport and Stein (1994), and Vieira et al (2010) |”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee (2004)
In the citing paper
“No significant differences in cell-mediated immunity were found in panic disorder patients after 6 weeks of CBT or CBT plus benzodiazepines (Koh and Lee, 2004).”
From Inflammatory markers changes following acceptance-based behavioral psychotherapy in generalized anxiety disorder patients: Evidence from a randomized controlled trial (2024) · cites this paper as Koh and Lee, 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · cited 1×
“of the Symptom Checklist-90 Revised (SCL-90-R) anxiety subscale [”
VAN BALKOM, A. J. L. M., BAKKER, A., SPINHOVEN, P., BLAAUW, B. M. J. W., SMEENK, S., & RUESINK, B. (1997) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199708000-00006 · Cited by 211
Central nervous system toxicity of interferon
Rohatiner, A. Z., Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.63 · Cited by 183
Heldt, E., Manfro, G. G., Kipper, L., Blaya, C., Maltz, S., Isolan, L., Hirakata, V. N., & Otto, M. W. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000067188 · Cited by 87
Kampman, M., Keijsers, G. P. J., Hoogduin, C. A. L., & Hendriks, G.-J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0904 · Cited by 87
Psychoimmunoendocrine Aspects of Panic Disorder
Brambilla, F., Bellodi, L., Ferna, G., Battaglia, M., Sciuto, G., Diaferia, G., Petraglia, F., Panerai, A., & Sacerdote, P. (1992) · Neuropsychobiology · doi:10.1159/000118890 · Cited by 78
Mefford, I. N., & Heyes, M. P. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90136-b · Cited by 77
Reduced Lymphocyte Proliferation and Interleukin-2 Production in Anxiety Disorders
Koh, K. B., & Lee, B. K. (1998) · Psychosomatic Medicine · doi:10.1097/00006842-199807000-00015 · Cited by 60
Self-citationImmune Cell Imbalance in Major Depressive and Panic Disorders
Marazziti, D., Ambrogi, F., Vanacore, R., Mignani, V., Savino, M., Palego, L., Cassano, G. B., & Akiskal, H. S. (1992) · Neuropsychobiology · doi:10.1159/000118891 · Cited by 55
Koh, K. B. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(97)00292-4 · Cited by 54
Self-citationOtto, M., Hong, J., & Safren, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396726 · Cited by 48
Anxiety and Immune Responsiveness
Linn, B. S., Linn, M. W., & Jensen, J. A. (1981) · Psychological Reports · doi:10.2466/pr0.1981.49.3.969 · Cited by 47
Circulating Lymphocyte Phenotypic Surface Markers in Anxiety Disorder Patients and Normal Volunteers
Rapaport, M. H. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00263-1 · Cited by 43
Serum cytokine and soluble interleukin‐2 receptors in patients with panic disorder
Rapaport, M. H., & Stein, M. B. (1994) · Anxiety · doi:10.1002/anxi.3070010106 · Cited by 41
La Via, M. F., Munno, I., Lydiard, R. B., Workman, E. W., Hubbard, J. R., Michel, Y., & Paulling, E. (1996) · Psychosomatic Medicine · doi:10.1097/00006842-199603000-00007 · Cited by 41
Immunological response to stress in agoraphobia and panic attacks
Surman, O. S., Williams, J. M., Sheehan, D. V., Strom, T. B., Jones, K. J., & Coleman, J. H. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90242-8 · Cited by 37
Biondi, M., & Picardi, A. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000067186 · Cited by 29
A comparative study of immune status in panic disorder patients and controls
Ramesh, C., Yeragani, V. K., Balon, R., & Pohl, R. B. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03166.x · Cited by 24
Locus of Control Orientation in Panic Disorder and the Differential Effects of Treatment
Bakker, A., Spinhoven, P., van der Does, W. A. J., van Balkom, A. J. L. M., & van Dyck, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000049350 · Cited by 22
The Effect of Vitamin B-Complex on Stress-induced Immune Alteration
Koh, K.-B., & Lew, S.-H. (1999) · Cited by 2
Self-citation
Cited by
Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond
Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J., & Jovanovic, T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.146 · Cited by 786
Anxiety disorders and comorbid medical illness
Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., et al. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.12.006 · Cited by 668
A Meta-Analytic Review of Adult Cognitive-Behavioral Treatment Outcome Across the Anxiety Disorders
Norton, P. J., & Price, E. C. (2007) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000253843.70149.9a · Cited by 612
Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1190867 · Cited by 347
“…corticotropin-releasing hormone; NE, norepinephrine; E, epinephrine; ACh, acetylcholine, TNF, tumour necrosis factor; IL1, interleukin-1; IL6, interleukin-6; þ, stimulation; , inhibition. before pharmacological treatment, but after treatment, no significant differences were seen (Koh & Lee 2004).”
BackgroundBroad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder
Hoge, E. A., Brandstetter, K., Moshier, S., Pollack, M. H., Wong, K. K., & Simon, N. M. (2009) · Depression and Anxiety · doi:10.1002/da.20564 · Cited by 343
Metadata
- Authors
- Koh, K. B., & Lee, Y.
- Affiliations
- Yonsei University (KR)
- ORCID
- Lee, Youngjoon
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 73
- Issue
- 5
- Pages
- 286-292
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2020016982
- Cited by
- 53
- References
- 22
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 2 · 2013: 3 · 2012: 3
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.karger.com
- Licence
- cc-by-nc-nd
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Keywords
- panic disorder, anxiety, cell-mediated immunity, cognitive behavioral therapy, ethyl loflazepate, benzodiazepines, interleukin-2, lymphocyte proliferation, phytohemagglutinin, immune function, combined psychotherapy and pharmacotherapy
- MeSH terms
- Adult, Benzodiazepines, Female, Humans, Immunity, Cellular, Interleukin-2, Male, Middle Aged, Phytohemagglutinins, Psychiatric Status Rating Scales, Cognitive Behavioral Therapy, Panic Disorder, Treatment Outcome, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.